Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast Cancer

Video

In Partnership With:

Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.

Antoinette R. Tan, MD, MHSc, chief, Breast Medical Oncology, co-director, the Phase I Program, Levine Cancer Institute, chief, Medical Oncology, Atrium Health, Carolinas Medical Center-Pineville, clinical professor, the Department of Medicine, the University of North Carolina, discusses the potential of the oral selective estrogen receptor degrader (SERD) elacestrant (RAD-1901) being investigated inthe phase 3 EMERALD trial (NCT03778931) in estrogen receptor (ER)–positive breast cancer.

The phase 3 trial compared the efficacy and safety of elacestrant to standard-of-care fulvestrant (Faslodex) in patients whose disease has advanced on at least 1 prior endocrine therapy. Moreover, a new drug application has been submitted to the FDA, seeking the approval of elacestrant in ER–positive/HER2–negative breast cancer, supported by the results of this phase 3 trial.

The primary end point of the study looked at progression-free survival (PFS) in patients, which included patients whose disease had ESR1 mutations, Tan says. Moreover, results of the study showed that elacestrant improved PFS in patients at both 6 and 12 months when compared with fulvestrant, Tan explains. Overall, this is encouraging data, as this oral SERD is showing efficacy in a patient population who had previously been exposed to a CDK4/6 inhibitor, Tan concludes

Related Videos
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center